Imperial College London


Faculty of MedicineDepartment of Brain Sciences

Professor of Molecular Neuroimaging







Burlington DanesHammersmith Campus





Roger Gunn is Professor of Molecular Neuroimaging in the Division of Brain Sciences at Imperial College London. Professor Gunn has a background in applied mathematics and his research focuses on the application of positron emission tomography (PET) and magnetic resonance imaging (MRI) technologies to the study of pathophysiology and drug development in humans. A particular focus is the development of molecular PET probes to image targets in the brain - this includes the discovery and validation of the novel probes themselves, the associated development of quantitative analysis methods and the application of these tools in clinical studies exploring disease processes and their treatment.

Professor Gunn received his undergraduate training in applied mathematics and a PhD in bio-mathematical modelling of Positron Emission Tomography (PET) data from the University of Warwick.  He has worked previously at the MRC Cyclotron Unit (London, UK),  held a faculty position at McGill University where he worked at the Montreal Neurological Institute before joining GSK in 2003 to help establish their Clinical Imaging Centre.In October 2011 he took up the position of Chief Scientific Officer and Head of Analysis at Imanova which is a joint venture between Imperial, UCL, Kings and the MRC targeted at providing high quality R&D imaging capabilities to the London Universities and Commercial organisations. He also holds a Visiting Professorship at Oxford University (Department of Engineering Science) and has published 120 peer reviewed journal articles in the field of imaging. Professor Gunn has served as a panel member for the MRC and on organising and programme committees at numerous conferences - he was recently Co-Chair of BrainPET 2011.



Jolly AE, Raymont V, Cole JH, et al., 2019, Dopamine D2/D3 receptor abnormalities after traumatic brain injury and their relationship to post-traumatic depression, Neuroimage: Clinical, Vol:24, ISSN:2213-1582

Mansur A, Rabiner EA, Comley RA, et al., 2019, Characterization of 3 PET tracers for Quantification of Mitochondrial and Synaptic function in Healthy Human Brain: 18F-BCPP-EF, 11C-SA-4503, 11C-UCB-J, Journal of Nuclear Medicine, ISSN:1535-5667

Venkataraman A, Mansur A, Lewis Y, et al., Evaluation of mitochondrial and synaptic function in Alzheimer’s disease (AD): a [18F]BCPP-EF, [11C]SA4503 and [11C]UCB-J PET study, Journal of Cerebral Blood Flow and Metabolism, Vol:39, ISSN:1559-7016, Pages:121-122


Erritzoe D, Godlewska BR, Rizzo G, et al., 2019, Reduced serotonin release in patients with major depression: a PET study with [11C]Cimbi-36 and d-amphetamine challenge, 29th International Symposium on Cerebral Blood Flow, Metabolism and Function / 14th International Conference on Quantification of Brain Function with PET (BRAIN and BRAIN Pet), SAGE PUBLICATIONS INC, Pages:548-549, ISSN:0271-678X

Pagano G, Wilson H, Mansur A, et al., 2019, Mitochondrial complex 1, sigma 1 receptor and synaptic vesicle protein 2A density in early de novo patients with Parkinson's disease: pilot PET data, 5th Congress of the European-Academy-of-Neurology (EAN), WILEY, Pages:532-532, ISSN:1351-5101

More Publications